Centessa Pharmaceuticals (CNTA)
(Delayed Data from NSDQ)
$9.54 USD
-0.32 (-3.25%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $9.56 +0.02 (0.21%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CNTA 9.54 -0.32(-3.25%)
Will CNTA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CNTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTA
Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics
CNTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect?
Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know
Other News for CNTA
Centessa price target raised by $3 at Morgan Stanley, here's why
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Centessa Pharmaceuticals (CNTA)
Leerink Partners Sticks to Their Buy Rating for Centessa Pharmaceuticals (CNTA)
Centessa Pharmaceuticals appoints John Crowley as finance chief
Centessa Pharmaceuticals Announces Executive Team Reshuffle and New CFO